Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...

What Is Tremfya, and Why Does It Matter? Tremfya (guselkumab) is a lab-made, dual-acting antibody medication that reduces inflammation by targeting the interleukin-23 (IL-23) protein and blocking a ...

Mild side effects of Tremfya include injection site reactions and upper respiratory infections. Though rare, Tremfya can also cause serious side effects, including severe infections. Your doctor may ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Low body surface area psoriasis in sensitive or highly visible areas is often prescribed only topical ...

Janssen has debuted the first safety and efficacy data on Tremfya in ulcerative colitis, and so far, prospects for a label expansion look good. The readout accompanies positive 48-week results in ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Additionally, for patients in the study's placebo group, who switched to TREMFYA ® at Week 24, the rate of radiographic progression from baseline to Week 24 (0.96) was reduced by 57% (to 0.41) from ...

Tremfya interacts with other biologic immunomodulator drugs, such as abatacept (Orencia) and canakinumab (Ilaris). Tremfya can also interact with tricyclic antidepressants (TCAs), such as ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

In addition, results showed 56 percent of TREMFYA q4w patients and 55 percent of TREMFYA q8w patients achieved at least 50 percent improvement in ACR score (utilizing NRI). 2 Among patients who had ...

Tremfya is a brand-name medication used to treat moderate to severe ulcerative colitis in adults by targeting a protein that reduces inflammation in the large intestine. Treatment with Tremfya ...